A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.

Abstract: The present invention relates to a drug for human use, having contraceptive and menstrual cycle controlling properties, characterized in that the said drug comprises N-acetyl-5-methoxytryptamine or melatonin, in a dose of 100-200 mg pro die, N-acetyl-2-bromo-5-methoxytryptamine or 2-bromomelatonin in a dose of 25-50 mg pro die N-acetyl-2-iodo-5-methoxytryptamine or 2-iodomelatonin, in a dose of 20-40 mg pro die, in association with a progestinic compound. The administration is carried out for 23 days, by using an association of 2-iodomelatonin and/or melatonin and/or 2-bromomelatonin and a progestinic compound, followed by 5 days in which only 2-iodomelatonin and/or melatonin and/or 2-bromomelatonin is administered; the drug having oncostatic preventive and therapeutic properties, in mammary tumours and melanomas, characterized by the use of 2-iodomelatonin, melatonin and 2-bromomelatonin respectively with doses of 20-40 mg, 100-200 mg, 25-50 mg pro die; and the said drug having moreover antikinetosic properties, and being characterized by the use of 2-iodomelatonin in a dose pro die of 2.5 mg, melatonin, in a dose pro die of 10 mg and 2-bromomelatonin in a dose pro die of 3.5 mg, either individually and/or in association with the acetyl coenzime A-(AcCoA), in a dose of 8-10 mg pro die.

Description: BACKGROUND OF THE INVENTION The present invention relates to methods for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having antikinetosic, oncostatic preventive and therapeutic properties for treatment of mammary tumours and melanomas, starting from melatonin. After years of studies and experiments, related to the mechanism of action of melatonin, this indole is at present considered as the most important hormonal product of the pineal gland. The developments in the field of receptor research have led to the localisation of two important receptor sites of melatonin in SNC: pars tuberalis of the pituitary gland, and the suprachiasmatic nuclei (SCN) of the hypothalamus. Intensive studies have discovered the biological basis for the mechanism of action of melatonin and its two halogen derivatives (2-bromo and 2-iodomelatonin). Experiments carried out by several researcher groups have confirmed some of the previous discoveries, and have shown that the ability of melatonin to inhibit reproduction, under given experimental conditions, can be related to a direct action of the indole on the hormone responsive elements in the SNC and the pituitary gland. Thus, from prior research it has been known that melatonin can potentially be used as a human contraceptive drug. In fact, recently performed research has shown the possibility of using melatonin in association with a progestinic compound (norethisterone), as a powerful contraceptive, which, moreover, provides several advantages such as a low conception risk (less than 1%), lower risk of vascular disturbances (no estrogenic compounds are used) and less painful premenstrual and menstrual periods as well as a less painful premenopause period (melatonin and agonists thereof are known to have sedative effects). Norethisterone alone, as well as other progestinic derivatives, have been used as contraceptives in the recent years, and they are generally known under the name "minipill". Norethisterone, when used as a "minipill", however has not provided remarkable results in preventing undesired pregnancies (about 2.35% conception risk). Other progestinic compounds, such as 1-norgestrel, have been found to provide better results, with reduced doses (0.08-0.16 mg). On the other hand, it has been found that melatonin, in order to express its contraceptive action, required comparatively high doses (100-200 mg). SUMMARY OF THE INVENTION Thus, the aim of the present invention is to provide such a method for preparing 2-iodomelatonin and 2-bromomelatonin, potent melatonin agonists According to one aspect of the present invention this aim, together with other objects, which will become more apparent hereinafter are achieved by the methods taught in the independent claims. Further features of the subject methods are defined in the subclaims. More specifically the inventive methods for the synthesis of 2-bromo and 2-iodomelatonin are carried out based on the following functional diagrams: SYNTHESYS OF 2-BROMELATONIN (N-acetyl-2-bromo-5-methoxytryptamine) To a solution of melatonin (1.16 g; 5mM) in anydrous acetic acid (10 ml) there is slowly added, under stirring, a solution of bromosuccinimide (NBS: 0.89 g; 5mM); in anhydrous acetic acid (30ml). The reaction mixture is stirred under nitrogen at room temperature for three hours. At the end it is cooled on an ice bath and neutralized to a pH 7 with a solution of 50% NaOH, still under nitrogen; a cream suspension is thereby obtained. The aqueous phase is extracted four times with chloroform; the combined organic phases are washed two times with a saturated solution of NaCl and dried on anhydrous sodium sulphate. The solvent is removed under reduced pressure, so as to provide 2 g of a raw product in the form of a brown-yellow oil. The raw product is purified by flash chromatography (silica gel; EtOAc: cyclohexane; 8:2) thereby providing 0.70 g (45% yield) of product. It is crystallized from EtOAc: hexane; mp: 146-149°C (on Kofler). The reaction can be followed by TLC, by using ethyl acetate as mobile phase. The NMR spectrum confirms the structure of the obtained product. SYNTHESIS OF 2-IODOMELATONIN (N-acetyl-2-iodo-5-methoxytryptamine To a solution of melatonin (2.32 g: 10 mM) in chloroform (70 ml) cooled at -20°C, there is added N-iodosuccinimide (NIS:2.25 g: 10 mM): the reaction mixture is stirred at -20°C for 4.5 hours. The organic solution is washed with saturated solution of sodium carbonate solution (1 time) and with water (two times) and then it is dried on anhydrous sodium sulphate. The solvent is removed under a reduced pressure and the raw material is purified by flash chromatography (anhydrous alumina; EtOAc) thereby providing 0.5 g of a product which is recrystallized from EtOAc with traces of hexane. There are obtained 0.4 g (yield 10-12%) of a product having a m. p. 142°C The NMR spectrum confirms the structure of the obtained product. TOXICITY: In the specific case of melatonin, acute toxicity tests have been performed in: 1) Rats, intraperitoneally DL50 = greater than 462 mg.Kg 2) Rats, per os DL50 = greater than 800 mg/Kg 3) Rabbits, intravenously DL50 = greater than394 mg/Kg (observation period 14 days) and the sub-acute toxicity in: 4) Rats subcutaneously DL50 = greater than 192 mg/Kg (observation period 25 days). The haematological, biochemical and electrophoretic tests, and the tests for determining the status and weight of organs, bone marrow, and the histologic tests have not shown any particular toxicity and, based on these observations, which show the low toxicity of the individual compounds and associations, a favourable opinion has been released about the starting of the clinical experimentation. With respect to the toxicity of 2-iodomelatonin and 2-bromomelatonin, the acute toxicity tests have been carried out: 1) in rats per os: DL50 greater than 200 mg/kg 2) in mice per os and intraperitoneally: DL50 greater than 100 mg/Kg. Moreover, all of the details related to the administering, as well as the illustrated doses can be changed depending on the specific patients to be treated without departing from the scope of the invention which is mainly based on methods of synthesizing 2-iodomelatonin, or 2-bromomelatonin and derivatives thereof, either individually and/or in association with a progesten in the contraceptive therapy and in the menstrual cycle controlling therapy, as well as in the oncostatic preventive therapy of mammary tumours and melanoma, and in the antikinetosic therapy.

Claims: A method for carrying out a synthesis of 2-iodomelatonin (i.e. N-acetyl-2-iodo-5-methoxytryptamine) for providing a drug having antikinetosic, oncostatic, preventive and therapeutic properties for treatement of mammary tumours and melanomas characterized in that said synthesis is defined by the following formula: A method for the synthesis of 2-iodomelatonin according to Claim 1, characterized in that said method comprises the steps of providing a solution of melatonin (2.32 g: 10 mM) in chloroform (70 ml), cooling this solution to -20°C: introducing into said cooled solution N-iodosuccinimide (NIS: 2.25 g: 10 mM) to provide a reaction mixture: stirring said mixture at -20°C and for a period of 4.5 hours: washing said organic solution with saturated sodium carbonate solution (1 time) and water (2 times) and then drying said washed organic solution on anhydrous sodium sulphate. A method for the synthesis of 2-iodomelatonin according to Claim 1, characterized in that said method comprises the further steps of removing the solvent from said mixture under reduced pressure, so as to provide a raw material: purifying said raw material by a flash chromatography (anhydrous alumina; EtOAc) to provide a desired amount (0.5 g) of a product which is recrystallized from EtOAC with traces of hexane, so as to provide 0.4 g (yield 10-12%) of a product having a m.p. of approx. 142°C. A method for the synthesis 2-bromomelatonin (N-acetyl-2-bromo-5-methoxytryptamine), characterized in that said synthesis is defined by the following formula: A method for the synthesis of 2-bromomelatonin, according to Claim 4, characterized in that said method comprises the steps of slowly introducing into a solution of melatonin (1.16 g; 5 mM ) in anhydrous acetic acid (10 ml), under stirring, a solution of bromosucinimide (NBS: 0.89 g: 5mM) in anhydrous acetic acid (30 ml). A method for the synthesis of 2-bromomelatonin, according to Claim, 4, characterized in that said method comprises the step of stirring said reaction mixture under nitrogen at room temperature for three hours: cooling said mixture on an ice bath, and neutralizing said cooled mixture to a pH 7 by using a 50% NaOH solution, under nitrogen, so as to provide a cream suspension. A method for the synthesis of 2-bromomelatonin according to Claim 4, characterized in that said method further comprises the step of extracting four times the aqueous phase by chloroform and washing two times the combined organic phases with a saturated NaCl solution, drying said combined organic phases on anhydrous sodium sulphate, and removing the solvent under reduced pressure so as to provide 2 g of a raw product in the form of a yellow-brown oil. A method for the synthesis of 2-bromomelatonin, according to Claim 4, characterized in that said method comprises the further step of purifying said raw product by flash chromatography (silica gel; EtOAc: cyclohexane; 8:2) so as to provide 0.70 g (yield 45%) of a product and then crystallizing said product (EtOAc: hexane): m.p. 146-149°C (on Kofler), the reaction being carried out by TLC, by using ethyl acetate as an eluent. A compound characterized in that it is 2-bromomelatonin.

Inventors: DI BELLA LUIGI I F L O S A S, DURANTI ERMANNO I F L O S A S, FRASCHINI FRANCO I F L O S A S, LAGUZZI ALDO I F L O S A S, STANKOV BOJIDAR I F L O S A S, DI BELLA, LUIGI, I.F.L.O. S.A.S., DURANTI, ERMANNO, I.F.L.O. S.A.S., FRASCHINI, FRANCO, I.F.L.O. S.A.S., LAGUZZI, ALDO, I.F.L.O. S.A.S., STANKOV, BOJIDAR, I.F.L.O. S.A.S.
Applicants: I F L O S A S DI GIORGIO E ALD, I.F.L.O. S.A.S. DI GIORGIO E ALDO LAGUZZI
Application year: 1991
Main classification: A61K31
IPC codes: A61K31, A61P13, C07D209, A61P35, A61P15